Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)

被引：0
|
作者：
Toshirou Nishida
Kuniaki Shirao
Akira Sawaki
Masato Koseki
Takeshi Okamura
Atsushi Ohtsu
Toshiro Sugiyama
Kunihisa Miyakawa
Seiichi Hirota
机构：
[1] Osaka University Graduate School of Medicine,Department of Surgery
[2] National Cancer Center Hospital,Department of Medical Oncology
[3] Aichi Cancer Center Hospital,Department of Gastroenterology
[4] National Hospital Organization Kure Medical Center,Department of Surgery
[5] National Kyushu Cancer Center,Department of Gastroenterological Surgery
[6] National Cancer Center Hospital East,Division of Gastrointestinal Oncology/Digestive Endoscopy
[7] Hokkaido University Graduate School of Medicine,Department of Gastroenterology
[8] National Cancer Center Hospital,Diagnostic Radiology Division
[9] Hyogo College of Medicine,Department of Surgical Pathology
来源：
International Journal of Clinical Oncology | 2008年 / 13卷
关键词：
Gastrointestinal stromal tumor; Imatinib; Phase II;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Efficacy and Safety of Imatinib Mesylate for Patients in the First Chronic Phase of Chronic Myeloid Leukemia: Results of a Japanese Phase II Clinical Study
    Yasuo Morishima
    Michinori Ogura
    Miki Nishimura
    Fumiharu Yazaki
    Masami Bessho
    Hideaki Mizoguchi
    Shigeru Chiba
    Hisamaru Hirai
    Tetsuzo Tauchi
    Akio Urabe
    Masatomo Takahashi
    Kazunori Ohnishi
    Toshiya Yokozawa
    Nobuhiko Emi
    Masami Hirano
    Chihiro Shimazaki
    Shinji Nakao
    Yasukazu Kawai
    Masahiro Fujimoto
    Hirokuni Taguchi
    Itsuro Jinnai
    Ryuzo Ohno
    International Journal of Hematology, 2004, 80 : 261 - 266
  • [22] Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors
    Yoo, Changhoon
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Beck, Mo Youl
    Kang, Yoon-Koo
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1367 - 1374
  • [23] Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors
    Changhoon Yoo
    Min-Hee Ryu
    Baek-Yeol Ryoo
    Mo Youl Beck
    Yoon-Koo Kang
    Investigational New Drugs, 2013, 31 : 1367 - 1374
  • [24] Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
    George, Suzanne
    von Mehren, Margaret
    Fletcher, Jonathan A.
    Sun, Jichao
    Zhang, Sen
    Pritchard, Justin R.
    Hodgson, John Graeme
    Kerstein, David
    Rivera, Victor M.
    Haluska, Frank G.
    Heinrich, Michael C.
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1268 - 1276
  • [25] A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST) following failure of at least imatinib and sunitinib
    Ganjoo, K. N.
    Villalobos, V. M.
    Kamaya, A.
    Fisher, G. A.
    Butrynski, J. E.
    Morgan, J. A.
    Wagner, A. J.
    D'Adamo, D.
    McMillan, A.
    Demetri, G. D.
    George, S.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 236 - 240
  • [26] Efficacy and safety of neoadjuvant imatinib therapy for patients with locally advanced rectal gastrointestinal stromal tumors: A multi-center cohort study
    Li, Weihao
    Li, Xinyue
    Yu, Kun
    Xiao, Binyi
    Peng, Jianhong
    Zhang, Rongxin
    Zhang, Lingfang
    Wang, Kun
    Pan, Zhizhong
    Li, Cong
    Wu, Xiaojun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [27] Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A single arm, multicenters, phase 2 trial.
    Li, Jian
    Zhou, Ye
    Zhang, Xinhua
    Wu, Xiaojun
    Zhou, Yongjian
    Liu, Xiufeng
    Zhang, Bo
    Wu, Xin
    Lin, Shen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [28] A phase II pilot study of Gleevec/Glivec (imatinib mesylate, STI-571) in patients with c-kit positive acute myeloid leukemia (AML).
    Fischer, T
    Beck, J
    Duyster, J
    Peschel, C
    Müller-Navia, J
    Jäger, E
    Knuth, A
    Gschaidmeier, H
    Huber, C
    BLOOD, 2002, 100 (11) : 561A - 561A
  • [29] The efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: A multicenter, retrospective study.
    Yang, Weili
    Qian, Haoran
    Yang, Litao
    Wang, Pengfei
    Qian, Hailong
    Chu, Binbin
    Liu, Zhuo
    Sun, Jingyu
    Wu, Dan
    Sun, Lifeng
    Zhou, Wenqiang
    Hu, Jingwei
    Chen, Xiaolei
    Shou, Chunhui
    Ruan, Lingxiang
    Yu, Jiren
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 800 - 800
  • [30] A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study
    Dy, GK
    Miller, AA
    Mandrekar, SJ
    Aubry, MC
    Langdon, RM
    Morton, RF
    Schild, SE
    Jett, JR
    Adjei, AA
    ANNALS OF ONCOLOGY, 2005, 16 (11) : 1811 - 1816
12345